Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Immunol Today. 1991 Nov;12(11):404-10.

Blocking IL-1: interleukin 1 receptor antagonist in vivo and in vitro.

Author information

  • 1Tufts University School of Medicine, New England Medical Center, Boston, MA 02111.

Abstract

Clinical and experimental evidence suggests that shock, arthritis, osteoporosis, colitis, leukemia, diabetes, wasting and atherosclerosis are mediated, in part, by interleukin 1 (IL-1). Inhibition of this cytokine has been a strategy for studying disease and for new drug development. A naturally-occurring IL-1 inhibitor (IL-1 receptor antagonist, IL-1ra) that blocks binding of IL-1 to its receptors has been cloned and produced in recombinant organisms. IL-1ra reduces the severity of sepsis, colitis, arthritis and diabetes in animals and is presently being tested in humans with arthritis, shock and myelogenous leukemia.

PMID:
1838480
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Write to the Help Desk